Hussman Strategic Advisors Inc. Purchases 31,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hussman Strategic Advisors Inc. boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 75.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,500 shares of the biopharmaceutical company's stock after buying an additional 31,500 shares during the period. Halozyme Therapeutics makes up 1.0% of Hussman Strategic Advisors Inc.'s holdings, making the stock its 12th biggest holding. Hussman Strategic Advisors Inc. owned about 0.06% of Halozyme Therapeutics worth $3,514,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. FSC Wealth Advisors LLC bought a new position in Halozyme Therapeutics during the third quarter worth $65,000. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter worth $69,000. CWM LLC increased its stake in Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company's stock valued at $88,000 after purchasing an additional 668 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 173.6% during the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 1,028 shares during the period. Institutional investors own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Benchmark restated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research note on Friday, November 1st. Finally, HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Halozyme Therapeutics Stock Up 0.5 %

Shares of NASDAQ HALO traded up $0.31 during trading on Friday, hitting $57.75. The stock had a trading volume of 1,299,523 shares, compared to its average volume of 1,313,186. The firm has a fifty day moving average of $53.46 and a two-hundred day moving average of $54.62. The company has a market capitalization of $7.11 billion, a PE ratio of 16.84, a PEG ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.72 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.